Does TRICARE Cover Lunesta (Eszopiclone)?

What Is Eszopiclone and Why Is It Prescribed?

Eszopiclone is the S-enantiomer of zopiclone and binds selectively to GABA-A receptor complexes containing alpha-1, alpha-2, alpha-3, and alpha-5 subunits, producing sedative and hypnotic effects [1]. The FDA approved eszopiclone (brand name Lunesta) without a duration-of-use restriction, making it one of the few approved hypnotics cleared for long-term management of chronic insomnia disorder [2].

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline on Pharmacologic Treatment of Chronic Insomnia states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults" [3]. That conditional recommendation is grounded in multiple randomized controlled trials.

Krystal et al. conducted a key 6-month, double-blind, placebo-controlled trial (N=788) demonstrating that eszopiclone 3 mg reduced sleep latency, increased total sleep time, and improved sleep quality scores relative to placebo throughout the entire study duration, with no evidence of efficacy loss over time [4]. A separate 2-night crossover study by Zammit et al. (N=436) confirmed that eszopiclone 3 mg cut subjective sleep latency by approximately 30 minutes vs. placebo (P<0.001) [5].

Chronic insomnia disorder affects roughly 10 to 15 percent of U.S. adults by DSM-5 criteria, with active-duty military and veterans carrying a disproportionately high burden due to deployment-related sleep disruption [6]. That clinical reality is directly relevant to any TRICARE beneficiary asking about coverage.

How TRICARE Structures Its Formulary

TRICARE uses a three-tier formulary administered by its pharmacy benefit manager. Tier 1 contains generic drugs dispensed free at military treatment facility (MTF) pharmacies. Tier 2 covers preferred brand-name drugs with modest copays. Tier 3 covers non-preferred brands at the highest copay level [7].

Generic eszopiclone became widely available after patent expiration in 2014. Because a therapeutically equivalent generic exists, TRICARE places brand-name Lunesta on Tier 3. A 30-day supply of generic eszopiclone at a TRICARE retail network pharmacy typically costs $11 to $14 for TRICARE Prime beneficiaries and $11 to $28 for TRICARE Select beneficiaries. The same supply obtained at an MTF pharmacy costs $0 under both plans [7].

The Defense Health Agency publishes the TRICARE Uniform Formulary, and any drug not on that formulary requires a non-formulary exception rather than a standard prior authorization [8]. Eszopiclone (generic) is on the formulary. Brand Lunesta is listed as a formulary alternative subject to Tier 3 cost-sharing unless a medical necessity exception is approved.

Prior Authorization Requirements for Brand Lunesta Under TRICARE

TRICARE requires prior authorization for brand-name Lunesta specifically. The generic form does not require PA at most TRICARE contractors. Prescribers submit PA requests through the TRICARE pharmacy contractor (Express Scripts, operating under the TRICARE Pharmacy Program) [9].

Standard PA criteria for brand Lunesta under TRICARE generally include:

1. A diagnosis of chronic insomnia disorder confirmed by the treating provider.
2. Documentation that the patient trialed generic eszopiclone (or an alternative Tier-1 sedative-hypnotic such as zolpidem immediate-release) for a minimum of 30 days.
3. A clinical reason why the brand formulation is medically necessary over the generic. This is difficult to justify pharmacologically because the active molecule is identical.
4. Prescriber attestation that the step-therapy alternatives were ineffective, not tolerated, or contraindicated.

The FDA-approved labeling for eszopiclone notes that the drug carries a risk of complex sleep behaviors (sleepwalking, sleep driving) and should not exceed 1 mg as starting dose in women or elderly patients [2]. If a patient experienced a serious adverse event on a specific formulation or dose, that history supports a PA narrative.

PA decisions under TRICARE are typically rendered within 3 business days for non-urgent requests and 24 hours for urgent clinical situations [9]. A denial triggers the appeal process described in a later section.

Step Therapy: What TRICARE Expects Before Approving Lunesta

Step therapy is the requirement to try and fail a lower-cost drug before access to a more expensive one is granted. TRICARE applies step therapy to brand Lunesta because generic eszopiclone is bioequivalent. The FDA defines therapeutic equivalents as products that are "pharmaceutical equivalents" whose "rate and extent of absorption do not show a significant difference" when administered in the same molar dose [10].

A first step typically involves a 30-day trial of generic eszopiclone 1 mg, 2 mg, or 3 mg depending on patient age and hepatic function. If the patient tolerates it without benefit, the prescriber documents failure and requests the brand. If the patient fails generic eszopiclone due to an adverse event, the prescriber may instead request a different hypnotic class (e.g., suvorexant, doxepin 3 or 6 mg) rather than brand Lunesta, because the molecule is the same.

The AASM guideline also recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment before any pharmacotherapy [3]. Some TRICARE regional contractors ask for documentation that CBT-I was offered or attempted before approving any hypnotic, including the generic. The Veterans Affairs and Department of Defense (VA/DoD) Clinical Practice Guideline for Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea (2019) likewise recommends CBT-I as the initial treatment, noting: "We recommend offering CBT-I as the initial treatment for chronic insomnia disorder" [11].

The HealthRX Step-Therapy Decision Map for TRICARE Lunesta Coverage:

• Step 0: Rule out secondary causes of insomnia (sleep apnea, restless legs, medication effects, psychiatric comorbidity).
• Step 1: Trial CBT-I for 4 to 8 weeks. Document completion or inability to access a trained therapist.
• Step 2: Trial generic eszopiclone (or zolpidem IR) for 30 days at an appropriate dose. Document outcome.
• Step 3: If Step 2 fails, prescriber submits PA with step-failure documentation. Brand Lunesta approval at this stage is still unlikely unless there is a formulation-specific clinical reason.
• Step 4: If brand Lunesta is the clinical target, consider requesting suvorexant or low-dose doxepin as an alternative that is pharmacologically distinct, which may receive faster PA approval.

TRICARE Copay Structure by Plan and Pharmacy Type

Understanding copay tiers prevents surprise bills. The following figures reflect the 2024 TRICARE Pharmacy copay schedule published by the Defense Health Agency [7]:

Generic eszopiclone (Tier 1):

• MTF pharmacy: $0 per 30-day supply
• TRICARE retail network: $11 (Prime) / $11 (Select)
• TRICARE mail order (Express Scripts): $0 per 90-day supply

Brand Lunesta (Tier 3, if approved):

• MTF pharmacy: $0 per 30-day supply (if stocked)
• TRICARE retail network: $43 (Prime) / $51 (Select) per 30-day supply
• TRICARE mail order: $20 per 90-day supply (Prime) / $29 per 90-day supply (Select)

Mail-order dispensing through the TRICARE Pharmacy Home Delivery program consistently yields the lowest out-of-pocket cost for beneficiaries who require a 90-day maintenance supply [7]. Providers writing a 90-day supply with three refills reduce the administrative burden on patients and maximize savings.

How to Appeal a TRICARE Denial for Lunesta

A denied PA or a step-therapy exception denial is not final. TRICARE provides a structured appeal pathway under 32 CFR Part 199 [12].

Level 1: Reconsideration by the Pharmacy Contractor. Submit within 90 days of the denial notice. Attach the prescriber's clinical letter, step-therapy failure documentation, and any relevant sleep study or specialist notes. The contractor must respond within 30 days.

Level 2: TRICARE Formal Grievance / Appeal to the Defense Health Agency. If the Level 1 reconsideration is denied, submit a written appeal to the DHA within 90 days of that denial. Include all Level 1 materials plus any new evidence. The DHA issues a final agency decision within 60 days.

Level 3: External Review / ALJ Hearing. For claims exceeding $300, beneficiaries may request a hearing before an Administrative Law Judge. This pathway is rarely used for a single hypnotic prescription but is available under federal regulation.

Practically speaking, appeals succeed most often when the prescriber documents a specific clinical reason tied to patient safety or therapeutic need. A letter stating "patient experienced rebound insomnia and next-morning impairment on zolpidem IR 5 mg but not on eszopiclone 2 mg" is more compelling than a general claim that brand Lunesta is preferred.

The National Sleep Foundation notes that untreated chronic insomnia increases risk of depression, cardiovascular disease, and occupational accidents [13]. For active-duty personnel, this safety argument can carry particular weight with a military medical reviewer.

Can You Use the Lunesta Manufacturer Savings Card with TRICARE?

No. Federal anti-kickback statutes and TRICARE regulations prohibit the use of pharmaceutical manufacturer savings cards, coupons, or copay assistance programs alongside any federally funded health benefit, including TRICARE [14]. This prohibition covers all GoodRx-type discount cards when TRICARE is the primary payer.

The only legal workarounds are:

1. Pay entirely cash. If a beneficiary opts out of using TRICARE for a specific fill, they may use a GoodRx or manufacturer coupon. Generic eszopiclone 3 mg (30 tablets) costs approximately $15 to $25 at major retail pharmacies under GoodRx pricing, which often beats the TRICARE Tier-3 copay for brand Lunesta. The trade-off: the cash-pay fill does not count toward any deductible or cost-share accumulator under TRICARE.
2. Switch to generic. Generic eszopiclone fills through TRICARE mail order are $0 for a 90-day supply. This eliminates any financial rationale for brand Lunesta unless there is a documented clinical reason.

A 2022 JAMA Internal Medicine analysis found that manufacturer copay coupons were available for 72% of top-selling brand-name drugs but that federal program exclusions made them unavailable to roughly 30% of commercially insured Americans who are also enrolled in Medicare, Medicaid, or TRICARE [15].

Eszopiclone Dosing, Safety, and Clinical Context

Prescribers submitting PA requests benefit from demonstrating familiarity with the approved dosing parameters. The FDA-approved label specifies [2]:

• Starting dose: 1 mg for elderly or debilitated patients, and for patients with severe hepatic impairment.
• Standard adult dose: 1 mg to 3 mg taken immediately before bed.
• Maximum dose: 3 mg per night.
• The 2 mg and 3 mg doses increase total sleep time and reduce wake after sleep onset (WASO) more than 1 mg in controlled trials.

The most common adverse effects in clinical trials were unpleasant taste (34% at 3 mg vs. 3% placebo), headache (21%), and somnolence (10%) [4]. The FDA added a boxed warning in 2019 for complex sleep behaviors, a risk shared across all non-benzodiazepine sedative-hypnotics [2].

Krystal et al. demonstrated that eszopiclone 3 mg maintained efficacy across a 6-month study period without tolerance development. Polysomnographic endpoints showed increased total sleep time (mean improvement 37 minutes vs. placebo), decreased WASO, and improved sleep stage architecture at months 1, 3, and 6 [4]. This long-term data profile is relevant for TRICARE PA requests because it supports extended prescribing without automatic dose escalation.

Drug interactions of clinical relevance include CYP3A4 inhibitors (e.g., ketoconazole, which increases eszopiclone AUC by approximately 2.2-fold), CNS depressants (additive sedation), and rifampicin (reduces eszopiclone exposure by approximately 80%) [2]. Prescribers should document any co-administered drugs that affect CYP3A4 when submitting a PA, as these can affect which dose is appropriate and may support a specific formulation request.

A meta-analysis by Huedo-Medina et al. (BMJ 2012, N=13 trials including 4,378 participants) found that non-benzodiazepine hypnotics produced a standardized mean difference in sleep quality of only 0.19 (95% CI 0.11 to 0.27) compared to placebo, and cautioned that effect sizes "may be too small to be of clinical significance" [16]. TRICARE medical reviewers are aware of this literature. A strong PA letter acknowledges the modest population-level effect size while documenting the individual patient's measurable response (e.g., sleep diary data, Insomnia Severity Index scores before and after trial).

The Insomnia Severity Index (ISI) is a validated 7-item questionnaire with scores ranging from 0 to 28; a score of 15 or above indicates moderate-to-severe clinical insomnia [17]. Including ISI scores at baseline and after the step-therapy trial is a concrete way to substantiate clinical response or failure in a PA submission.

Alternatives TRICARE May Prefer Over Brand Lunesta

TRICARE reviewers generally look for a pharmacologically distinct alternative before approving a brand drug whose generic is on the formulary. Alternatives with different mechanisms include:

Suvorexant (Belsomra): An orexin receptor antagonist approved for sleep onset and maintenance insomnia. A randomized trial by Herring et al. (Sleep Medicine 2016, N=254) found suvorexant 20 mg reduced WASO by a mean of 28 minutes vs. 5 minutes for placebo at week 4 (P<0.001) [18]. TRICARE covers suvorexant with PA; it is pharmacologically distinct from eszopiclone and may receive approval where brand Lunesta does not.

Low-dose doxepin (Silenor 3 mg / 6 mg): A histamine H1 antagonist at these doses, FDA-approved for sleep maintenance insomnia. The Roth et al. trial (Sleep 2007, N=221) showed doxepin 6 mg increased total sleep time by a mean of 32 minutes vs. placebo (P<0.001) [19]. Generic low-dose doxepin is available and sits on Tier 1 of the TRICARE formulary at many contractors.

Zolpidem immediate-release (generic): TRICARE Tier 1 for generic. Widely used as the first step-therapy agent. The FDA restricts the approved dose to 5 mg in women and elderly patients due to next-morning impairment data [2].

If a patient truly requires brand Lunesta specifically because all pharmacologically distinct alternatives have failed or are contraindicated, that clinical narrative is strong enough to support a PA. The key is documentation: dated prescriptions, pharmacy fill records, and brief clinical notes on each trialed agent.